Fixed combination of repaglinide and metformin in the management of type 2 diabetes

References

• RendellMSJovanovicLTargeting postprandial hyperglycemiaMetabolism20065591263128116919548
   PubMed Web of Science ®Google Scholar
• MonnierLLapinskiHColetteCContributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c)Diabetes Care200326388188512610053
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) GroupLancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• HolmanRRPaulSKBethelMAMatthewsDRNeilHA10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med2008359151577158918784090
   PubMed Web of Science ®Google Scholar
• StrattonIMAdlerAINeilHAAssociation of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ2000321725840541210938048
   PubMed Web of Science ®Google Scholar
• GersteinHCMillerMEByingtonRPEffects of intensive glucose lowering in type 2 diabetesN Engl J Med2008358242545255918539917
   PubMed Web of Science ®Google Scholar
• PatelAMacMahonSChalmersJIntensive blood glucose control and vascular outcomes in patients with type 2 diabetesN Engl J Med2008358242560257218539916
   PubMed Web of Science ®Google Scholar
• DuckworthWAbrairaCMoritzTGlucose control and vascular complications in veterans with type 2 diabetesN Engl J Med2009360212913919092145
   PubMed Web of Science ®Google Scholar
• SkylerJSBergenstalRBonowROIntensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart AssociationDiabetes Care200932118719219092168
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) UK Prospective Diabetes Study (UKPDS) GroupLancet199835291318548659742977
   PubMed Web of Science ®Google Scholar
• RaoADKuhadiyaNReynoldsKFonsecaVAIs the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studiesDiabetes Care20083181672167818458139
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapyDiabetes Care200831111
   Web of Science ®Google Scholar
• MelikianCWhiteTJVanderplasADeziiCMChangEAdherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapyClin Ther200224346046711952029
   PubMed Web of Science ®Google Scholar
• BlondeLWogenJKreilickCSeymourAAGreater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metforminDiabetes Obes Metab20035642443114617228
   PubMed Web of Science ®Google Scholar
• GromadaJDissingSKofodHFrokjaer-JensenJEffects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cellsDiabetologia1995389102510328591815
   PubMed Web of Science ®Google Scholar
• WolffenbuttelBHRepaglinide – a new compound for the treatment of patients with type 2 diabetesNeth J Med199955522923410593133
   PubMed Web of Science ®Google Scholar
• FuhlendorffJRorsmanPKofodHStimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processesDiabetes19984733453519519738
   PubMed Web of Science ®Google Scholar
• DamsboPClausonPMarburyTCWindfeldKA double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patientsDiabetes Care199922578979410332683
   PubMed Web of Science ®Google Scholar
• MarburyTHuangWCStrangePLebovitzHRepaglinide versus glyburide: a one-year comparison trialDiabetes Res Clin Pract199943315516610369424
   PubMed Web of Science ®Google Scholar
• LandgrafRBiloHJMullerPGA comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureasEur J Clin Pharmacol199955316517110379630
   PubMed Web of Science ®Google Scholar
• Van GaalLFVan AckerKLDe LeeuwIHRepaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetesDiabetes Res Clin Pract200153314114811483229
   PubMed Web of Science ®Google Scholar
• LiJTianHLiQImprovement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients – a randomized controlled double-blind and double-dummy multicentre clinical trialDiabetes Obes Metab20079455856517587398
   PubMed Web of Science ®Google Scholar
• RosenstockJHassmanDRMadderRDRepaglinide versus nateglinide monotherapy: a randomized, multicenter studyDiabetes Care20042761265127015161773
   PubMed Web of Science ®Google Scholar
• BaileyCJTurnerRCMetforminN Engl J Med199633495745798569826
   PubMed Web of Science ®Google Scholar
• JohansenKEfficacy of metformin in the treatment of NIDDM. Meta-analysisDiabetes Care1999221333710333900
   PubMed Web of Science ®Google Scholar
• InzucchiSEMaggsDGSpollettGREfficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitusN Engl J Med1998338138678729516221
   PubMed Web of Science ®Google Scholar
• SaenzAFernandez-EstebanIMataixAAusejoMRoqueMMoherDMetformin monotherapy for type 2 diabetes mellitusCochrane Database Syst Rev20053CD00296616034881
   PubMed Web of Science ®Google Scholar
• RudovichNNLeyck DiekenMGRochlitzHPfeifferAFEnhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitusExp Clin Endocrinol Diabetes2004112739540015239026
   PubMed Web of Science ®Google Scholar
• MosesRSlobodniukRBoyagesSEffect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetesDiabetes Care199922111912410333912
   PubMed Web of Science ®Google Scholar
• MosesRGAchieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targetsClin Ther200830355255418405794
   PubMed Web of Science ®Google Scholar
• ReboussinDMGoffDC JrLipkinEWThe combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial resultsDiabet Med200421101082108915384954
   PubMed Web of Science ®Google Scholar
• RaskinPKlaffLMcGillJEfficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metforminDiabetes Care20032672063206812832314
   PubMed Web of Science ®Google Scholar
• HoelscherDChuPLLynessWFixed-dose combination tablet of repaglinide and metformin is bioequivalent to concomitantly administered individual tablets of repaglinide and metformin: randomized, single-blind, three-period crossover study in healthy subjectsClin Drug Investig2008289573582
   Web of Science ®Google Scholar
• ReilleySChangC-TLynessWSingle-dose pharmacokinetics of a repaglinide/metformin fixed-dose combination tablet in fasted and fed conditions 68th Scientific Session of the ADA June 6–10, 2008 San Francisco, CA, USA Abstr no. 2133-0
   Google Scholar
• RaskinPHangYLynessWTwice-daily and thrice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycemic control 68th Scientific Session of the ADA June 6–10, 2008 San Francisco, CA, USA Abstr no. 2153–0
   Google Scholar
• RaskinPHangYLynessWTwice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycemic control similar to a rosiglitazone/metformin fixed-dose combination tablet 68th Scientific Session of the ADA June 6–10, 2008 San Francisco, CA, USA Abstr no. 2154–0
   Google Scholar
• FordanSHangYLynessWRaskinPTwice-daily vs thrice-daily dosing of a repaglinide/metformin fixed-dose combination tablet in T2DM subjects previously treated with monotherapy vs dual therapy 68th Scientific Session of the ADA June 6–10, 2008 San Francisco, CA, USA Abstr no. 2155–0
   Google Scholar
• RheeCHangYLynessWRaskinPRepaglinide/metformin fixed-dose combination tablet vs rosiglitazone/metformin fixed-dose combination tablet in T2DM subjects evaluated by prior OAD treatment regimen 68th Scientific Session of the ADA June 6–10, 2008 San Francisco, CA, USA Abstr no. 2125–0
   Google Scholar
• LundSSTarnowLFrandsenMImpact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetesEur J Endocrinol20081581354618166815
   PubMed Web of Science ®Google Scholar
• BuseJBTanMHPrinceMJEricksonPPThe effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetesDiabetes Obes Metab20046213315614746579
   PubMed Web of Science ®Google Scholar
• DeegMATanMHPioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studiesPPAR Res2008200852046518769492
   PubMed Web of Science ®Google Scholar
• DaileyGEGlyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetesExpert Opin Pharmacother2003481417143012877648
   PubMed Web of Science ®Google Scholar
• RaskinPOral combination therapy: repaglinide plus metformin for treatment of type 2 diabetesDiabetes Obes Metab200810121167117718494804
   PubMed Web of Science ®Google Scholar